文献速递浆细胞疾病

克隆性免疫球蛋白CDR3序列在多发性骨髓瘤MRD追踪中的稳定性与独特性

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
PubMed 文献 · Am J Hematol · 2019-10-21

该研究分析905例浆细胞骨髓瘤及健康对照样本的免疫球蛋白CDR3序列,发现所有患者基线均存在克隆性重链和/或轻链表达,3.2%存在相关亚克隆。45例患者101份连续样本中优势克隆CDR3序列随时间保持 identical,尽管49%患者全外显子测序显示克隆演化。体细胞超突变和非模板插入是轻链克隆独特性的最重要决定因素,多数患者可识别潜在可追踪序列。

要点

  • 基线优势克隆CDR3序列在长期追踪中保持稳定,不受克隆演化影响
  • 轻链克隆独特性主要由体细胞超突变和非模板插入决定
  • 多数患者可识别可追踪的轻链序列,支持IGH和轻链联合MRD监测

核心结论

  • 基线识别的优势克隆CDR3序列是长期追踪恶性克隆的可靠生物标志物,包括IGH和大多数轻链克隆。

研究设计与样本

  • 分析905例浆细胞骨髓瘤和健康对照样本的免疫球蛋白库,聚焦CDR3区域。
  • 45例患者共101份连续样本用于纵向稳定性分析,部分患者行全外显子测序评估克隆演化。

主要发现

  • 所有患者基线均检测到克隆性重链和/或轻链表达,3.2%存在一个或多个与主克隆相关的亚克隆。
  • 45例患者101份连续样本中优势克隆CDR3序列随时间保持 identical,尽管49%患者全外显子测序显示差异克隆演化。
  • 亚克隆CDR3变异频率低且活动性多发性骨髓瘤中无随时间演化,提示该阶段肿瘤细胞未受抗体亲和力成熟的选择压力。
  • 体细胞超突变和非模板插入是轻链克隆独特性的最重要决定因素,多数患者可识别潜在可追踪序列。

关键数值与推荐

  • 克隆性重链和/或轻链表达在基线所有患者中均检出,亚克隆相关比例为3.2%。
  • 45例患者101份连续样本中优势克隆CDR3序列保持 identical,49%患者全外显子测序显示克隆演化。

临床怎么用

  • 基线识别优势克隆CDR3序列可用于多发性骨髓瘤MRD长期追踪,包括IGH和多数轻链克隆。
  • 轻链序列独特性评估应关注体细胞超突变和非模板插入,以确定可追踪性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimal residual disease (MRD) tracking, by next generation sequencing of immunoglobulin sequences, is moving towards clinical implementation in multiple myeloma. However, there is only sparse information available to address whether clonal sequences remain stable for tracking over time, and to what extent light chain sequences are sufficiently unique for tracking. Here, we analyzed immunoglobulin repertoires from 905 plasma cell myeloma and healthy control samples, focusing on the third complementarity determining region (CDR3). Clonal heavy and/or light chain expression was identified in all patients at baseline, with one or more subclones related to the main clone in 3.2%. In 45 patients with 101 sequential samples, the dominant clonal CDR3 sequences remained identical over time, despite differential clonal evolution by whole exome sequencing in 49% of patients. The low frequency of subclonal CDR3 variants, and absence of evolution over time in active multiple myeloma, indicates that tumor cells at this stage are not under selective pressure to undergo antibody affinity maturation. Next, we establish somatic hypermutation and non-templated insertions as the most important determinants of light chain clonal uniqueness, identifying a potentially trackable sequence in the majority of patients. Taken together, we show that dominant clonal sequences identified at baseline are reliable biomarkers for long-term tracking of the malignant clone, including both IGH and the majority of light chain clones.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rustad EH, Misund K, Bernard E, et al. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. Am J Hematol. 2019. PMID: 31571261. doi:10.1002/ajh.25641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。